Neuroprotective and Disease-Modifying Effects of the Triazinetrione ACD856, a Positive Allosteric Modulator of Trk-Receptors for the Treatment of Cognitive Dysfunction in Alzheimer’s Disease
International Journal of Molecular Sciences · 06.07.2023 · 24 (13) · 11159
DOI: 10.3390/ijms241311159 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 06.07.2023. Verfasst von Cristina Parrado Fernandez und 9 weiteren Autor:innen. Beteiligte Einrichtung: AlzeCure Pharma AB, Hälsovägen 7, 141 57 Huddinge, Sweden. Hauptthemen laut MEDLINE: Alzheimer Disease, Neuroblastoma, Neuroprotective Agents, Cognitive Dysfunction. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Demenz
Abstract (Originalsprache)
The introduction of anti-amyloid monoclonal antibodies against Alzheimer’s disease (AD) is of high importance. However, even though treated patients show very little amyloid pathology, there is only a modest effect on the rate of cognitive decline. Although this effect can possibly increase over time, there is still a need for alternative treatments that will improve cognitive function in patients with AD. Therefore, the purpose of this study was to characterize the triazinetrione ACD856, a novel pan-Trk positive allosteric modulator, in multiple models to address its neuroprotective and potential disease-modifying effects. The pharmacological effect of ACD856 was tested in recombinant cell lines, primary cortical neurons, or animals. We demonstrate that ACD856 enhanced NGF-induced neurite outgrowth, increased the levels of the pre-synaptic protein SNAP25 in PC12 cells, and increased the degree of phosphorylated TrkB in SH-SY5Y cells. In primary cortical neurons, ACD856 led to increased levels of phospho-ERK1/2, showed a neuroprotective effect against amyloid-beta or energy-deprivation-induced neurotoxicity, and increased the levels of brain-derived neurotrophic factor (BDNF). Consequently, administration of ACD856 resulted in a significant increase in BDNF in the brains of 21 months old mice. Furthermore, repeated administration of ACD856 resulted in a sustained anti-depressant effect, which lasted up to seven days, suggesting effects that go beyond merely symptomatic effects. In conclusion, the results confirm ACD856 as a cognitive enhancer, but more importantly, they provide substantial in vitro and in vivo evidence of neuroprotective and long-term effects that contribute to neurotrophic support and increased neuroplasticity. Presumably, the described effects of ACD856 may improve cognition, increase resilience, and promote neurorestorative processes, thereby leading to a healthier brain in patients with AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- AlzeCure Pharma AB, Hälsovägen 7, 141 57 Huddinge, Sweden.
- Division of Neuroscience, Care and Society, Department of Neurogeriatrics, Karolinska Institutet, 171 77 Solna, Sweden.
ORCID-Profile: Johan Sandin, Gunnar Nordvall, Pontus Forsell
Zitieren
APA
Parrado Fernandez, C., Juric, S., Backlund, M., Dahlström, M., Madjid, N., Lidell, V., Rasti, A., Sandin, J., Nordvall, G., & Forsell, P. (2023). Neuroprotective and Disease-Modifying Effects of the Triazinetrione ACD856, a Positive Allosteric Modulator of Trk-Receptors for the Treatment of Cognitive Dysfunction in Alzheimer’s Disease. International Journal of Molecular Sciences, 24(13), 11159. https://doi.org/10.3390/ijms241311159
Vancouver
Parrado Fernandez C, Juric S, Backlund M, Dahlström M, Madjid N, Lidell V, et al. Neuroprotective and Disease-Modifying Effects of the Triazinetrione ACD856, a Positive Allosteric Modulator of Trk-Receptors for the Treatment of Cognitive Dysfunction in Alzheimer’s Disease. International Journal of Molecular Sciences. 2023;24(13):11159. doi:10.3390/ijms241311159
BibTeX
@article{ParradoFernandez2023,
author = {Parrado Fernandez, Cristina and Juric, Sanja and Backlund, Maria and Dahlström, Märta and Madjid, Nather and Lidell, Veronica and Rasti, Azita and Sandin, Johan and Nordvall, Gunnar and Forsell, Pontus},
title = {Neuroprotective and Disease-Modifying Effects of the Triazinetrione ACD856, a Positive Allosteric Modulator of Trk-Receptors for the Treatment of Cognitive Dysfunction in Alzheimer’s Disease},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {13},
pages = {11159},
doi = {10.3390/ijms241311159}
}
EUVIMED